申请人:Nippon Chemiphar Co., Ltd.
公开号:EP3404021A1
公开(公告)日:2018-11-21
A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker:
wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2, provide that n and m are not 0 and 2 at the same time.
由以下通式(I)代表的化合物、该化合物的同系物或立体异构体、其药学上可接受的盐或其溶液可用作电压依赖性 T 型钙通道阻滞剂:
其中 A 代表可具有取代基的融合环,该融合环由 5 元杂芳基或 5 元或 6 元杂环和苯环或类似物组成,5 元杂芳基具有 1 至 3 个相同或不同的杂原子作为成环元素,具有至少一个取代基,例如具有 1 至 8 个碳原子并被 1 至 5 个卤素原子取代的烷氧基;R 代表氢原子或类似物;B 代表 CR5(Q1) 或 NQ2,其中 Q1 代表可能具有取代基的苯并咪唑基;Q2 代表可能具有取代基的具有 1 至 8 个碳原子的烷基、可能具有取代基的杂芳基或类似物;R0、R1、R2、R3、R4 和 R5 各代表氢原子或类似物;n 和 m 各代表 0、1 或 2,但 n 和 m 不能同时为 0 和 2。